Here's Why You Should Retain Boston Scientific (BSX) Now
https://www.zacks.com/stock/news/2195111/here-s-why-you-should-retain-boston-scientific-bsx-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2195111
Dec 07, 2023 - Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.
0
OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing
https://www.zacks.com/stock/news/2194705/orthopediatrics-kids-introduces-unit-for-non-surgical-bracing?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194705
Dec 07, 2023 - OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.
0
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
https://www.zacks.com/stock/news/2194846/here-s-why-you-should-retain-opko-health-opk-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2194846
Dec 07, 2023 - OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.
0
Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden
https://www.zacks.com/stock/news/2195277/quest-diagnostics-dgx-cdc-to-assess-hepatitis-c-burden?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195277
Dec 08, 2023 - Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
0
AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
https://www.zacks.com/stock/news/2195558/amn-healthcare-s-amn-new-tie-up-to-boost-patient-outcome?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195558
Dec 08, 2023 - AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
0
Masimo's (MASI) ORi Favored by Study for PaO2 Information
https://www.zacks.com/stock/news/2196904/masimo-s-masi-ori-favored-by-study-for-pao2-information?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196904
Dec 12, 2023 - Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
0
Charles River (CRL) Expands 3D In Vitro Services Via New Deal
https://www.zacks.com/stock/news/2197217/charles-river-crl-expands-3d-in-vitro-services-via-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197217
Dec 13, 2023 - Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
0
Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?
https://www.zacks.com/stock/news/2197283/integer-holdings-corporation-itgr-hit-a-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-2197283
Dec 13, 2023 - Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
0
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
https://www.zacks.com/stock/news/2197564/here-s-why-you-should-retain-exact-sciences-exas-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197564
Dec 13, 2023 - Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
0
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
https://www.zacks.com/stock/news/2197534/qiagen-s-qgen-strategic-alliances-aid-amid-macro-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2197534
Dec 13, 2023 - QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.
0